Genmab climbs on Phase II daratumumab data

Genmab A/S (CSE:GEN; OTCBB:GMXAY) rose DKK46 (11%) to DKK471 in Copenhagen after partner Janssen Biotech Inc. reported preliminary results

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE